Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211684 | 0.93 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2RECQLKDM4EHPGD | |
| SCHEMBL1992679 | 0.83 | MEN1 (0.43) | ALDH1A1SMN1; SMN2RECQLKDM4EHPGD | |
| SCHEMBL2212160 | 0.82 | ACACB (0.41) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL2990475 | 0.78 | ADORA3 (0.42) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL31647297 | 0.78 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2RECQLKDM4EMAPT | |
| SCHEMBL27599861 | 0.77 | L3MBTL1 (0.40) | ALDH1A1KDM4EHPGDMAPTL3MBTL1 | |
| SCHEMBL7983660 | 0.77 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RECQLKDM4EHPGD | |
| SCHEMBL16505479 | 0.77 | KDM4E (0.56) | ALDH1A1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL10588005 | 0.76 | LMNA (0.55) | ALDH1A1SMN1; SMN2RECQLKDM4EHPGD | |
| SCHEMBL27529060 | 0.76 | RAD52 (0.44) | ALDH1A1SMN1; SMN2RECQLKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490355-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-7825124-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-11-02 | — | — | US | disclosed |
| US-7786123-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-08-31 | — | — | US | disclosed |
| US-20090318463-A1 | Indolylmaleimide Derivatives | ALBERT RAINER | 2009-12-24 | — | — | US | disclosed |
| EP-1337527-B1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-2070921-A1 | Indolylmaleimide derivatives as protein kinase c inhibitors | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-7358253-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2008-04-15 | — | — | US | disclosed |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | ALBERT RAINER | 2007-08-16 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| CN-1253449-C | indolylmaleimide derivatives as protein kinase C inhibitors | NOVARTIS AG (CH) | 2006-04-26 | — | — | CN | disclosed |
| EP-1490355-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-20040053949-A1 | Indolylmaleimide derivatives | ALBERT RAINER (CH) | 2004-03-18 | — | — | US | disclosed |
| CN-1478087-A | Indolylmaleimide derivatives as protein kinase C inibitors | ��˹��ŵ�� | 2004-02-25 | — | — | CN | disclosed |
| US-6645970-B2 | Preventing T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer | NOVARTIS AG (CH) | 2003-11-11 | — | — | US | disclosed |
| WO-2003082859-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
| EP-1337527-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | Novartis AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-20030069424-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2003-04-10 | — | — | US | disclosed |
| WO-2002038561-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318463-A1 | Indolylmaleimide Derivatives | NFATC1, INMT, IDO1 | ALDH1A1 1752/4885SMN1; SMN2 3033/4885RECQL 2847/4885 |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | NFATC1, HLA-DRB1, INMT | ALDH1A1 1866/4885SMN1; SMN2 4644/4885RECQL 2447/4885 |
| US-20070032507-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | ALDH1A1 3744/4885SMN1; SMN2 1884/4885RECQL 4029/4885 |
| US-20030069424-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | ALDH1A1 1752/4885SMN1; SMN2 3033/4885RECQL 2847/4885 |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | NFATC1, CD4, LCK | ALDH1A1 3642/4885SMN1; SMN2 4221/4885RECQL 4570/4885 |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | MYLK2, LCK, DGKK | ALDH1A1 3764/4885SMN1; SMN2 1937/4885RECQL 4269/4885 |
| US-20040053949-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | ALDH1A1 1752/4885SMN1; SMN2 3033/4885RECQL 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.